Mesa Laboratories Inc

While the long and medium-term trends remain bullish in Stage 2, recent price action has pulled back below the short EMAs and into the 50 SMA support area. Short-term timing is neutral, and execution should be deferred until price reclaims and accepts above the 9/21 EMAs. We will stalk pullbacks into the rising EMAs or the 50 SMA for a favorable entry.

• ↑30.8% annual EPS growth projection in a resilient sterilization market
• ↑$0.16 quarterly dividend underscores stable shareholder returns
• ↓High price volatility indicates unpredictable share swings